Acelyrin (NASDAQ: SLRN) was initiated at Overweight with a $29 price target by Morgan Stanley in a note Tuesday.Analyst Vikram ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE